• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600613.SS
Share

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Stocks

CN¥ 8.18Last Updated 12.10.2026

Issuer Rating

4/7
Performance

Average

Risk

Moderate

Recommendation

Hold

Market Cap

CN¥ 624.57M

CN¥ 8.18
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Weak growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., through its various subsidiaries, functions as a pharmaceutical manufacturing holding and investment entity within China. The company's operations encompass the research, development, and production of a broad spectrum of medications. Its therapeutic focus includes pharmaceuticals for oncology, cardiovascular and cerebrovascular conditions, respiratory issues (such as colds and coughs), pediatric care, and antifungal treatments, alongside general health tonics. The firm's product portfolio features both prescription-only drugs and readily available over-the-counter (OTC) remedies. Established in Shanghai, China, in 1992, the company continues to operate from this location.

Company Valuation

Slightly overvalued
3/7

Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EB

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.10.2026 19:22

A Crisis-Proof Formula for Shaping the Future: Why the Nobel Prize in Economics Was Awarded

12.10.2026 19:20

Is it time to buy stocks? Goldman Sachs has upgraded its recommendation for the next three months

12.10.2026 18:58

Oppenheimer recommends buying Fastly stock ahead of the earnings report and the release of the iconic game GTA

12.10.2026 18:03

Shares of Nebius' competitor surged following news of a contract with Anthropic

12.10.2026 17:57

China's CXMT has unsettled investors in Micron and Samsung, causing their stock prices to fall. What's going on?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026